A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. METHODS: In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks. The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. Secondary end points included resolution of NASH and regression of fibrosis. RESULTS: A total of 247 patients underwent randomization, of whom 103 (42%) had type 2 diabetes mellitus and 188 (76%) had significant (moderate) or advanced fibrosis. The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs. placebo, 55% vs. 33%, P = 0.007; 800-mg dose vs. placebo, 48% vs. 33%, P = 0.07). The results favored both the 1200-mg and 800-mg doses of lanifibranor over placebo for resolution of NASH without worsening of fibrosis (49% and 39%, respectively, vs. 22%), improvement in fibrosis stage of at least 1 without worsening of NASH (48% and 34%, respectively, vs. 29%), and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% and 25%, respectively, vs. 9%). Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups. The dropout rate for adverse events was less than 5% and was similar across the trial groups. Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo. CONCLUSIONS: In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both have been tested successfully on phase II clinical trials, proving they are well-tolerated by patients and showing MASH resolution without worsening of fibrosis (165, 166).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [166]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most importantly, resolution of NASH without worsening of fibrosis (49% with 1200 mg Lanifibranor, vs. 39% with 800 mg vs. 22% Placebo), improvement in fibrosis of at least one stage without worsening of NASH (48% vs. 34% vs. 22%) and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% vs. 25% vs. 9%) all favored the study drug as compared to placebo.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pan-PPAR agonist lanifibranor demonstrated significant MASH resolution and fibrosis improvement in clinical trials, though it was associated with weight gain [3,136].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“Diarrhea, nausea, peripheral edema, anemia and weight gain were all seen more frequently in patients receiving Lanifibranor [59].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Finally and most recently the Pan‐PPAR agonist Lanifibranor reached the primary endpoint of a decrease in SAF‐A score of at least two points in a large Phase 2b Trial [59]—a dose‐dependent effect was seen with more patients achieving the primary endpoint with 1200 mg versus 800 mg.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 4×
“Increase in aminotransferase level§§ 3 (4) 5 (6) 1 (1)”
InfluentialSelf-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citationNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Self-citationFriedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Self-citation
Research works printed but not linked: 2
- Sanyal AJ, Anstee QM, Trauner M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (NASH). Hepatology 2020; 72: 67A-68A. abstract 90.
- Ratziu V, de Guevara L, Safadi R, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double- blind, placebo-controlled phase 2b trial. Nat Med (in press).
Cited by
Items 501–600 of 830
Jia, W., Wu, S., Wang, K., Wang, X., Li, J., Xu, H., & Ji, L. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157474 · Cited by 6
Han, J., Chen, J., Hu, H., Song, Y., Chen, M., Zhao, D., Shan, W., Zhang, Q., & Xu, L. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157519 · Cited by 5
Ouyang, R., Li, X., Hao, J., Lin, J., Lan, H. Y., Peng, J., Li, X., Tian, Z., & Sun, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1708240 · Cited by 5
Li, D., & Zhang, X. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000846 · Cited by 10
Llach, J., Sòria, A., Graupera, I., & Cardenas, A. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2632873 · Cited by 5
The gene regulatory networks shaping macrophage plasticity and altered function in fibrosis
Kolostyák, Z., & Nagy, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1767954 · Cited by 6
Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps
Praveen Sandeep Raj, R., John, R., Manoharan, F., Janeela, A. M., Goel, A., & Kapoor, N. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102107 · Cited by 6
Akuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., 疋田隼人, et al. (2026) · Hepatology Research · doi:10.1111/hepr.70188 · Cited by 8
“These include farnesoid X receptor agonists [108] (e.g., obeticholic acid), thyroid hormone receptor‐β agonists [109] (e.g., resmetirom), and pan‐PPAR agonists [110] (e.g., lanifibranor).”
Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
Ren, R., Liang, X., & Wei, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00486-5 · Cited by 6
Yang, K., Kim, H., Shim, Y., Ryu, T., & Kim, C. W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1186582 · Cited by 7
“Indeed, many potential drugs are under phase III clinical trials, including pan-peroxisome proliferatoractivated receptor agonist (lanifibranor) (Francque et al., 2021), glucagon-like peptide-1 receptor agonist (semaglutide) (Newsome et al.”
BackgroundXiong, M., Zhang, Z., Cui, J., Du, X., Chen, Y., & Zhang, T. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116916 · Cited by 5
Wang, Y., Zheng, J., Long, Y., Wu, W., & Zhu, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115989 · Cited by 5
Arnold, J., Idalsoaga, F. J., Díaz, L. A., Cabrera, D., Francisco Barrera, M., Arab, J. P., & Arrese, M. A. (2024) · Current Hepatology Reports · doi:10.1007/s11901-023-00629-0 · Cited by 6
Malandris, K., Papandreou, S., Vasilakou, D., Kakotrichi, P., Sarakapina, A., Kalopitas, G., Karagiannis, T., Γιουλεμέ, Ό., Bekiari, E., Liakos, A., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16559 · Cited by 5
Exploring the potential of drug repurposing for liver diseases: A comprehensive study
Ali, F. E. M., Abdel‐Reheim, M. A., Hassanein, E. H. M., El‐Aziz, M. K. A., Althagafy, H. S., & Badran, K. S. A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122642 · Cited by 7
Susman, S. J., Santoso, B., & Makary, M. S. (2024) · Biomedicines · doi:10.3390/biomedicines12102226 · Cited by 7
Metabolic-dysfunction associated steatotic liver disease (MASLD)
De, A., Panigrahi, M. K., Duseja, A. K., & Singh, S. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26711-6.00031-7 · Cited by 5
Huang, R., Zhang, C., Mo, X., & Rao, H. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003417 · Cited by 5
Analyzing MASLD interventional clinical trial registration based on the ClinicalTrials.gov database
Du, H., Huang, J., Wang, Y., Wang, C., Wang, Y., Hou, L., Li, Y., Li, Y., & Su, Q. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03732-2 · Cited by 7
“However, relevant clinical trials suggest that dual and pan-PPAR agonists may exhibit broader and more effective therapeutic benefits [36, 37].”
Kim, J. W., Raggi, P., Carreau, A., Wharton, S., CHENG, A. Y. Y., & Swain, M. G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70117 · Cited by 6
“27,28 However, many healthcare professionals (HCPs) who manage patients with advanced liver disease do not necessarily have the expertise to treat MASH-associated CMD.”
Romero‐Gómez, M. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2022.09.004 · Cited by 13
Self-citationGrzych, G., Bernard, L., Lestrelin, R., Tailleux, A., & Staels, B. (2022) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2022.09.005 · Cited by 6
Current and investigational drugs in early clinical development for portal hypertension
Sakiani, S., Heller, T., & Koh, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.974182 · Cited by 5
“In the NATIVE study, a phase 2b trial evaluating the effects of lanifibranor in patients with NASH, 48% of patients receiving 1,200 mg and 39% of patients receiving 800 mg had improvement in fibrosis scores (95).”
MethodNon-alcoholic Steatohepatitis Diagnosis and Treatment – Current Concepts
Ijacu, A. M., Gagiu, L. G., Staicu, I. M., Zugravu, C., & Constantin, C. (2024) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.1.1 · Cited by 4
Chang, E., Zhu, Y., Wei, W., Huai, J., Lv, T.-S., Lou, Y., & Zhou, X. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118850 · Cited by 4
Hu, W., Gu, M., Li, H., Li, H., Kan, J., Zhang, L., Ding, Q., & Zhu, Y. Z. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100125 · Cited by 5
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4
Self-citationZheng, Z., Li, Y., & Pan, Y. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03117-8 · Cited by 4
Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan
Seko, Y., & Yamaguchi, K. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02401-9 · Cited by 4
“Lanifibranor reduced hepatic fat and improved insulin resistance in patients with T2D and achieved MASH resolution without worsening fibrosis [122, 123].”
Richard, K. S. E., Rohilla, S., Gade, R., Arias, F., & Rom, O. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01425-z · Cited by 4
Al-Mughalles, A. S., Ma, J., Ma, H., Zhang, C., Xiao, H., Ma, X., Zhang, Q., Jia, C., Han, H., Ding, B., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02997-8 · Cited by 4
“…trial demonstrated efficacy at 24 weeks, achieving MASH resolution without fibrosis worsening in 49% of patients versus 21% on placebo, and fibrosis improvement of at least one stage in 48% versus 29% on placebo, its clinical adoption requires a clear-eyed assessment of its limitations [116].”
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Wei, S., He, Y., Luo, C., & He, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924392 · Cited by 4
Current therapeutic landscape and future treatment perspectives of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10672-8 · Cited by 7
“Conversely, lanifibranor has demonstrated promising results in a 6-month phase II study, improving glucose metabolism, MASH resolution and fibrosis, leading to phase III evaluation for advanced MASLD 90 .”
Self-citationDahlqvist, G., Declerck, S., Lepour, M., Delorme, A., Collard, A., Tréfois, P., & Lanthier, N. (2026) · Liver International · doi:10.1111/liv.70862 · Cited by 4
Self-citationXiao, L., Liang, C., Gao, J., Wang, Y., Guo, Y., Chen, K., & Jia, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21973 · Cited by 4
“A phase IIb trial supports the potential benefits of lanifibranor in patients with NASH [11].”
BackgroundLanifibranor Reduces Inflammation and Improves Dyslipidemia in Lysosomal Acid Lipase-Deficient Mice
Bradić, I., Vujić, N., Kuentzel, K. B., Habisch, H., Pirchheim, A., Akhmetshina, A., Henderson, J., Madl, T., Deshmukh, A. S., & Kratky, D. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.05.006 · Cited by 4
Novel dynamic and static biomarkers for the assessment of liver disease severity in MASLD
Amato, F., Marano, M., Gjini, K., VAIRA, L., Bugianesi, E., & Armandi, A. (2024) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.24.03186-9 · Cited by 4
Self-citationDinerman, S., & Shu, Y. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5010007 · Cited by 6
“…(NCT03008070), 24 weeks of 800 mg and 1200 mg lanifibranor treatment showed dose-dependent improvement in MASH resolution and fibrosis mitigation by at least 1 stage in MASH patients with liver steatosis (25% of patients with 800 mg and 35% with 1200 mg treatment vs. 9% with placebo; n = 247) [66].”
Apodaka‐Biguri, M., Simão, A. L., González‐Romero, F., Mestre, D., Rodrigues, P. M., Aurrekoetxea, I., Gómez‐Santos, B., Buqué, X., Nieva‐Zuluaga, A., de Gauna, M. R., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001461 · Cited by 5
“For instance, research on nuclear PPAR receptors has led to the development of several PPAR agonists, such as lanifibranor (PAN-PPAR), which is still in clinical trials, [41] or saroglitazar, a new PPAR α and PPAR γ agonist [42] , which might be useful for MASLD.”
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Mangia, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70271 · Cited by 4
“Liver biopsy was performed at baseline, and patients were randomised 1:1 with stratification by T2D [53].”
InfluentialExtrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Shenoy, A., Ahmed, A., & Kim, D. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.73 · Cited by 10
Stefan, N., & Roden, M. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2076-0145 · Cited by 7
Heldens, A., Casteleyn, C. R., Onghena, L., Antwi, M. B., Neyt, S., Descamps, B., Vanhove, C., Verhelst, X., Raevens, S., Vlierberghe, H. V., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117826 · Cited by 8
Self-citationNon-alcoholic fatty liver disease - opportunities for personalized treatment and drug development
Kemas, A. M., Youhanna, S. C., & Lauschke, V. M. (2022) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2022.2053285 · Cited by 5
Chew, N., Muthiah, M. D., & Sanyal, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00003-6 · Cited by 5
Self-citationNon-invasive liver fibrosis tests in non-alcoholic fatty liver disease
Liguori, A., Zoncapè, M., & Tsochatzis, E. A. (2022) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2022.8718/2022 · Cited by 5
Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
Brennan, P. N., The University of Edinburgh, C. F. R. M., NHS Tayside, N. H. A. M. S., The University of Dundee, D. O. M. A. C. M., Dillon, J. F., NHS Tayside, N. H. A. M. S., The University of Dundee, D. O. M. A. C. M., McCrimmon, R., NHS Tayside, N. H. A. M. S., & The University of Dundee, D. O. M. A. C. M. (2022) · European Endocrinology · doi:10.17925/ee.2022.18.2.148 · Cited by 3
“The primary endpoint was a reduction of at least 2 points in component A of the Steatosis, Activity, Fibrosis scoring system.(22) Exploratory secondary endpoints included regression of fibrosis or resolution of NASH.”
MethodTargeting macrophages in liver fibrosis
González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835489 · Cited by 3
Bandyopadhyay, S. K., Samajdar, S. S., Chaudhuri, S., & Das, S. (2024) · Hospital Practice · doi:10.1080/21548331.2024.2412513 · Cited by 3
“In a recent phase 2b trial involving patients with active MASH, the use of lanifibranor improved histologic activity, score, liver enzymes, and the majority of blood lipids, inflammatory and fibrosis biomarkers [18].”
Hao, W., Chen, L., Li, T., & Lv, G. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002963 · Cited by 3
Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV
Wang, H., Jiang, Y., Wang, S., Lu, C., Tang, L., Gu, T., & Shu, S. (2025) · Acta Pharmaceutica · doi:10.2478/acph-2025-0022 · Cited by 3
“Other promising drugs in development include lanifibranor (a pan-PPAR agonist) in phase III clinical trials (100), and semaglutide (a GLP-1 receptor agonist) (101).”
Wang, P.-J., Fan, H., Jiang, B., Shi, J., Cai, X., Ji, L., Yan, Q., & Liu, C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118406 · Cited by 3
Zhu, W., Chang, W., Chen, T., Li, M., Han, Z., Sun, N., Fang, W. Y., & Wang, D. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120571 · Cited by 7
Alsharif, O., & Rombouts, K. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00037-9 · Cited by 3
Recent advances in the design, development and therapeutic applications of PPARγ agonists
Ghannam, I. A. Y., Abdel‐Mohsen, H. T., & Ali, I. H. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2571022 · Cited by 3
Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?
Elmustafa, F., Tyagi, M., Kaur, H., Blaney, H. L., Xie, C., Jalil, S., & Singal, A. K. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00712-8 · Cited by 6
“Nota-Table have shown potential in improving hepatic fat, inflamma - tion, and fibrogenesis, with antifibrotic effects observed in phase II/III trials [112, 113].”
Zacharia, G. S., Ashraf, M. H., Sosa, F., Jacob, A., & Patel, H. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i4.110827 · Cited by 3
Zhu, B. J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1753393 · Cited by 3
Zhang, C., Luo, Y., Xiong, Y., Chen, L., Zhao, H., Qiu, Z., & Yang, Y. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c09366 · Cited by 3
Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions
Qu, J., Qin, W., Dong, M., Ma, Z., Li, S., Liu, R., Chen, R., Li, C. H., & Li, X. (2026) · MedComm · doi:10.1002/mco2.70750 · Cited by 4
“Most encouragingly, lanifibranor treatment in Phase II trials resulted in significant improvements in levels of inflammation and fibrosis in MASH, particularly in highly active MASH patients with moderate or advanced liver fibrosis [ 52 ].”
Cobbold, J., Miller, H., Hallsworth, K., Manousou, P., Marjot, T., Allison, M. E., Anstee, Q. M., Armstrong, M., Avery, L., Azzu, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00077-4 · Cited by 6
Self-citationTang, M., Ma, Y., & Wang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1829315 · Cited by 3
Jarvis, H., Brennan, P., Casanovas, T., Casler, K., Desai, M., Evans, P. H., Dillon, J. F., Grattagliano, I., Hallsworth, K., Hebditch, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00015-4 · Cited by 5
Pharmacological treatment of MASH
Stefan, N., & Targher, G. (2026) · Diabetologia · doi:10.1007/s00125-026-06796-1 · Cited by 6
“%) compared with placebo [58].”
The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents
Qasim, A., Alataa, R., Veena, F., & Shehi, E. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1850915 · Cited by 4
Molecular mechanisms and pathogenesis of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10529-0 · Cited by 10
“Clarifying this is important, as novel therapies currently being studied in clinical trials such as pan-PPAR 115 or THRβ agonists 116,117 and liver-targeted mitochondrial uncoupling agents 90,94,118,119 aim to enhance hepatic mitochondrial oxidation.”
Self-citationHow far are we from an approved drug for nonalcoholic steatohepatitis?
Méndez‐Sánchez, N., Pal, S. C., & Córdova‐Gallardo, J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206953 · Cited by 3
A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine model
Wang, S. Z., Hirsch, T. I., Fligor, S. C., Tsikis, S. T., Pan, A., Quigley, M., Mitchell, P. D., Gura, K. M., Fraser, D. A., & Puder, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-98200-y · Cited by 3
“With respect to liver disease, PPAR-targeted therapies are currently under development for patients with metabolic dysfunction-associated steatohepatitis and are approved for the treatment of primary biliary cholangitis 32,33 .”
Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 4
“Both 1200 mg and 800 mg doses led to greater MASH resolution and fibrosis improvement compared to placebo, with similar results in patients with and without T2DM [46].”
Lanifibranor and NASH resolution
Kotsiliti, E. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00544-z · Cited by 3
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség. II. Kezelés
Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32480 · Cited by 3
“– Lanifibranor: pán- PPAR-agonista, NAFLD-ben ha-tását jelenleg vizsgálják [17, 23].”
Wang, Y., Yu, H., Cen, Z., Zhu, Y., & Wu, W. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100267 · Cited by 3
Bentsa, T. М. (2023) · Modern Gastroenterology · doi:10.30978/mg-2023-6-59 · Cited by 3
The Perspective of PPAR Dual/Pan Agonists as Therapeutic Drugs against NAFLD
Honda, A., & Ishii, I. (2022) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.22-00159-1 · Cited by 2
Challenges in the management of MetALD after liver transplantation
Cucco, M., Becchetti, C., Scaravaglio, M., Dispinzieri, G., Bolis, F., Bagalà, L., Strollo, M., Orlando, M., Perricone, G., Mazzarelli, C., et al. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.144 · Cited by 2
MASLD/MASH—New mechanisms and treatments
Zhang, X., Tsui, Y., & Ng, I. O. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000770 · Cited by 2
“[10] Recently, Barb et al investigated the effect of lanifibranor on insulin resistance (IR) and intrahepatic triglyceride (IHTG) content in patients with type 2 diabetes and MASLD.”
Screening for MASLD in patients with type 2 diabetes: is an early diagnosis a good diagnosis?
Nwoguh, C. A., Byrne, C. D., Reinson, T., & Buchanan, R. M. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2546597 · Cited by 2
“These include peroxisome proliferator-activated receptor agonists [39] and multiple incretin-based therapies such as semaglutide [40], a glucagon-like peptide-1 (GLP-1) receptor agonist; tirzepatide [41], a dual glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory…”
PPARidgm shifts in the treatment of metabolic dysfunction–associated steatotic liver disease
Abushamat, L. A., & Barb, D. (2025) · Hepatology · doi:10.1097/hep.0000000000001511 · Cited by 2
Dual-PPARα/δ agonist H11 alleviates tendinopathy via modulating the Nrf2/HO-1/GPX4 pathway
Yang, L., Yang, S., Liu, H., Zhang, Y., Li, Z., Lü, J., Jiang, Q. Y., & Xu, X. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.10.301 · Cited by 3
Wood, E. M., Akande, R. O., Iqbal, I., & Albert, S. G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70314 · Cited by 2
“We evaluated drugs that would be clinically available and did not consider phase 2 or 3 drugs such as the pan-PPAR agonist lanifibranor, 37 the FGF21 analogues pegozafer-min 38 or efruxifermin.”
Évolution de la nomenclature des maladies hépatiques stéatosiques : vers un changement de paradigme
Halfon, P. (2025) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2025.12.003 · Cited by 2
Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects
Piazzolla, V., Napolitano, A., & Mangia, A. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.152 · Cited by 2
Wang, W.-T., Tian, J.-R., Gao, S., Wang, M.-B., Luo, Y., & Li, X. (2026) · Metabolites · doi:10.3390/metabo16020092 · Cited by 2
“[87].”
MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management—A Narrative Review
Ștefan, A. G., Mitrea, A., Clenciu, D., Vladu, I. M., Roșu, M. M., Timofticiuc, D. C. P., Gheonea, T. C., Efrem, I. C., Amzolini, A. M., Vladu, B. E., et al. (2026) · Medicina · doi:10.3390/medicina62020325 · Cited by 5
“Lanifibranor, a pan-PPAR agonist, has demonstrated dose-dependent MASH resolution alongside regression of hepatic fibrosis stage and is currently under investigation in a phase 3 trial [81,145].”
Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV: A Scoping Review
Jahagirdar, V., Parajuli, P., Hargrove, S., & Sterling, R. K. (2026) · Livers · doi:10.3390/livers6010012 · Cited by 3
“Lanafibrinor, a pan-PPAR agonist, remains investigational following positive phase 2b results. achieved 49% MASH resolution (vs. 22% with placebo, p < 0.01) and 48% fibrosis improvement (vs. 29% with placebo, p < 0.01) in 247 patients with biopsy confirmed MASH and F1–F3 fibrosis [106].”
InfluentialA transdisciplinary framework for managing metabolic dysfunction associated steatotic liver disease
Kouser, S., Sharma, S. V., Bhanu, A., Kukkupuni, S. K., & Vishnuprasad, C. N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1767844 · Cited by 2
“…antioxidants, and anti-inflammatory agents are actively investigated for MASLD management, but none have demonstrated clinically significant improvement in liver outcomes across diverse patient populations (Musso et al., 2017; Francque et al., 2021; Loomba et al., 2023, 2024; Sanyal et al., 2025).”
Ezz-Eldin, Y. M., Azouz, A. A., Khalaf, M. M., & Ewees, M. G. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2638333 · Cited by 2
“…histology-based scores for fibrosis, activity, and steatosis at the 1200-mg dosage after 24 weeks. in addition, it improves lipid profile and iR [217]. the phase 3 NAtiv3(Nct04849728) clinical trial is currently being performed. the first part of the study aims to evaluate the ability of…”
Advances in the Pharmacologic Management of MASLD
Madhankumar, S., & Asma, A. (2026) · Gastroenterology Insights · doi:10.3390/gastroent17010017 · Cited by 2
“Importantly, lanifibranor resulted in NASH resolution and fibrosis improvement [70].”
Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis
Lin, J., Huang, Y., Xu, B., Huang, C., Teng, F., Yuan, Y., Zhang, J., & Zhang, H. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70206 · Cited by 2
“In recent years, the therapeutic landscape for MASH has expanded rapidly, encompassing THR-β agonists [4], incretin-based agents (GLP-1 receptor agonists [5], dual/triple agonists [15, 16]), SGLT2 inhibitors [9], and emerging compounds such as pan-PPAR agonists [17] and FGF21 analogs [18, 19].”
Early Adoption and Prescribing Patterns of Resmetirom: A Multi‐Institutional National Analysis
Solpari, K., Gouda, Z., Saggese, A., Buckholz, A. P., Sharaiha, R. Z., Kumar, S. R., & Kushner, T. (2026) · Liver International · doi:10.1111/liv.70580 · Cited by 2
“Concurrently, the pipeline includes promising agents with distinct mechanisms of action, such as the pan-PPAR agonist lanifibranor and novel FGF21 analogues, which aim to address metabolic and fibrotic drivers of disease [6, 7].”
Alzaki, A. A., Alqahtani, M., Aman, E., Asiri, G. M., Jibril, M. H. A., Desoky, R. M., Alqahtani, S. A., Suhaqi, L., Alkhalid, S. A., Alshareef, D. Y., et al. (2026) · Cureus · doi:10.7759/cureus.106038 · Cited by 3
“FGF21 analogues (efruxifermin, pegbelfermin) and pan-PPAR agonists (lanifibranor) have shown promising histologic and metabolic signals, making them potential partners in future regimens targeting steatosis, inflammation, and fibrosis [31-33].”
Hu, J., Dai, W., Xu, Z., Jia, Z., Li, F., Jiang, Y., Song, X., Chen, S., Zhou, G., Lei, D., et al. (2026) · Advanced Materials · doi:10.1002/adma.202511786 · Cited by 5
“Lanifibranor, a PPARγ agonist, is emerging as a promising therapeutic agent due to its broad application and advantages in treating fibrotic and inflammatory diseases [25].”
Zhao, S., Tian, F., Yu, L., Li, Z., Hou, J. Y., Wei, Y., Cui, H., Cui, S., & Ma, X. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04326-w · Cited by 4
“Following detailed evaluation, 5 placebo-controlled phase 2 or 3 RCTs met our inclusion criteria (tirzepatide: 1 [17], lanifibranor: 1 [19], resmetirom: 3 [24–26]).”
Roles of peroxisome proliferator-activated receptors (PPARs) in pancreatic metabolic diseases
Han, X., Geng, Y., Li, Y., Meng, X., & Jiao, J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108192 · Cited by 4
Emerging multi-target strategies and dual agonists of PPAR-α/γ modulation in Type 2 diabetes
Arora, P., Tyagi, A., Kumar, V., Arulsamy, S., Kaushik, M., & Kumar, S. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146281 · Cited by 2
André‐Dumont, S., & Lanthier, N. (2026) · Liver International · doi:10.1111/liv.70680 · Cited by 3
“To date, in clinical trials of treatments for MASLD, liver biopsy remains the gold standard as the primary outcome to assess the efficacy [47, 113, 114].”
Self-citationMAFLD/MASLD: Past, Present, and Future
Wong, V. W. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70619 · Cited by 2
Cardiovascular disease in metabolic-associated fatty liver disease
Adams, L. A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000803 · Cited by 2
Chen, L., Chen, Y., Wang, B., Yang, Z., Cai, Z., Wang, X., Sun, L., Li, Z., & Wang, G. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117533 · Cited by 2
Metadata
- Authors
- Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., Lanthier, N., Alkhouri, N., Moreno, C., Schattenberg, J. M., Stefanova-Petrova, D., Vonghia, L., Rouzier, R., Guillaume, M., Hodge, A., Romero-Gómez, M., Huot-Marchand, P., Baudin, M., Richard, M.-P., Abitbol, J.-L., Broqua, P., Junien, J.-L., & Abdelmalek, M. F.
- Affiliations
- Cliniques Universitaires Saint-Luc (BE)
- From Antwerp University Hospital and the Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp (S.M.F., L.V.), and Service d’Hépato-Gastroentérologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (N.L.) and Cliniques Universitaires de Bruxelles–Hôpital Erasme, Université Libre de Bruxelles (C.M.), Brussels — all in Belgium; the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom (P. Bedossa, Q.M.A.); Pitie–Salpétriêre Hospital, Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris (V.R.), Centre Hospitalier Universitaire Rangueil, Toulouse (M.G.), and Inventiva Pharma, Daix (P.H.-M., M.B., M.-P.R., J.-L.A., P. Broqua, J.-L.J.) — all in France; the Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy (E.B.); Virginia Commonwealth University, Richmond (A.J.S.); the University of California San Diego, La Jolla (R.L.); Pinnacle ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1547-1558
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3207086349
- Cited by
- 801
- References
- 33
- Citations by year
- 2026: 171 · 2025: 197 · 2024: 156 · 2023: 150 · 2022: 119 · 2021: 7
- FWCI
- 77.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc-nd)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Inventiva Pharma S.A., Daix, France
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- lanifibranor, nonalcoholic steatohepatitis, liver fibrosis regression, NASH resolution, type 2 diabetes, dose comparison, liver enzymes, PPAR agonists, fibrosis stage
- MeSH terms
- Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Sulfonamides, Body Mass Index, Peroxisome Proliferator-Activated Receptors, Benzothiazoles, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.